+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Albumin Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797848
The global albumin market value in 2022 was USD 5.30 billion and is anticipated to grow at a CAGR of 6.2% during the forecast period of 2023-2031, driven by the growing demand for albumin-based drug formulations across the globe. The global albumin market size is anticipated to reach a value of USD 9.20 billion by 2031.

Global Albumin Market: Introduction

Albumin is a globular protein that is synthesized in the liver and constitutes approximately 60% of the total protein content in the blood plasma. It plays a crucial role in maintaining oncotic pressure and regulating the transport of various substances such as hormones, drugs, and nutrients throughout the body. Albumin is extracted from human plasma or produced through recombinant technology and is used in various medical applications, including fluid replacement therapy, drug delivery, and as a plasma expander. It is also used in the manufacturing of vaccines and for the treatment of chronic conditions such as liver disease and hypoalbuminemia.

Albumin Market Scenario

The global market for albumin has experienced significant growth in recent years, driven by factors such as the increasing prevalence of chronic diseases, growing demand for albumin-based drug formulations, and advancements in albumin production techniques.

North America: The largest market for albumin, driven by factors such as the advanced healthcare industry, high prevalence of chronic diseases, and growing demand for albumin-based therapeutic products.

Europe: The second-largest market, with increasing demand for albumin due to a growing aging population, a supportive regulatory framework, and an expanding biopharmaceutical sector.

Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of chronic diseases, and growing investments in healthcare infrastructure and biopharmaceutical research.

Albumin Market Segmentations

Market Breakup by Type

  • Bovine Serum Albumin
  • Human Serum Albumin
  • Recombinant Serum Albumin

Market Breakup by Application

  • Drug Delivery
  • Therapeutics
  • Culture Media Ingredients
  • Vaccine Ingredients
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Albumin Market

Increasing prevalence of chronic diseases: The growing incidence of chronic diseases, such as liver disease and hypoalbuminemia, has led to a rising demand for albumin-based therapeutic products, driving market growth.

Growing demand for albumin-based drug formulations: The increasing preference for albumin as a drug carrier due to its biocompatibility, stability, and solubility has boosted the demand for albumin-based drug formulations, fuelling market growth.

Advancements in albumin production techniques: The development of new production techniques, such as recombinant technology and advanced fractionation methods, has improved the efficiency and quality of albumin production, further driving market growth.

Competitor Landscape

The report gives an in-depth analysis of the key players involved in the albumin market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Akron Biotech
  • Takeda Pharmaceutical Company Limited
  • Baxter International, Inc
  • Biotest AG
  • Celgene Corporation
  • Novozymes A/S
  • CSL Behring
  • Grifols, S.A
  • Baxalata Incorporated
  • Octapharma AG
  • Sigma-Aldrich Corporation
  • Mitsubishi Tanabe Pharma

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Albumin Market Overview
3.1 Global Albumin Market Historical Value (2016-2022)
3.2 Global Albumin Market Forecast Value (2023-2031)
4 Global Albumin Market Landscape
4.1 Global Albumin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Albumin Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Applications
4.2.3 Analysis by Region
5 Global Medical Cannabis Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Albumin Market Segmentation
6.1 Global Albumin Market by Type
6.1.1 Market Overview
6.1.2 Bovine Serum Albumin
6.1.3 Human Serum Albumin
6.1.4 Recombinant Serum Albumin
6.2 Global Albumin Market by Application
6.2.1 Market Overview
6.2.2 Drug Delivery
6.2.3 Therapeutics
6.2.4 Culture Media Ingredients
6.2.5 Vaccine Ingredients
6.2.6 Others
6.3 Global Albumin Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Albumin Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Albumin Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Albumin Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Albumin Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Albumin Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Akron Biotech
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Takeda Pharmaceutical Company Limited
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Baxter International, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Biotest AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Celgene Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novozymes A/S
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 CSL Behring
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Grifols, S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Baxalata Incorporated
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Octapharma AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sigma-Aldrich Corporation
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Mitsubishi Tanabe Pharma
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Albumin Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Akron Biotech
  • Takeda Pharmaceutical Company Limited
  • Baxter International, Inc.
  • Biotest AG
  • Celgene Corporation
  • Novozymes A/S
  • Csl Behring
  • Grifols, S.A.



Table Information